Linda L. Neuman - 14 Nov 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Chief Medical Officer
Signature
/s/ James Kastenmayer, by power of attorney
Issuer symbol
SYRE
Transactions as of
14 Nov 2022
Net transactions value
$0
Form type
4
Filing time
27 Jan 2023, 17:20:39 UTC
Next filing
24 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +25,000 $0.000000 25,000 14 Nov 2022 Common Stock 25,000 $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options will vest as to 1/4th of the total shares on November 14, 2023, and then 1/48th of the shares will vest monthly thereafter, such that the option will become fully vested on November 14, 2026, subject to the Reporting Person's provision of service to the issuer on each vesting date.